In this study, we developed a murine monoclonal antibody targeting human TM4SF4 (anti-hTM4SF4 mAb), designated 2B7, which exhibited potent anti-cancer effects in NSCLC both in vitro and in vivo. This evidence concerns the gene TM4SF4 and non-small cell lung carcinoma.